{"id":"https://openalex.org/W2005448885","doi":"https://doi.org/10.1158/0008-5472.can-07-0669","title":"A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity","display_name":"A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity","alternate_titles":[],"publication_year":2008,"publication_date":"2008-01-01","ids":{"openalex":"https://openalex.org/W2005448885","doi":"https://doi.org/10.1158/0008-5472.can-07-0669","mag":"2005448885","pmid":"https://pubmed.ncbi.nlm.nih.gov/18172313"},"language":"en","primary_location":{"id":"doi:10.1158/0008-5472.can-07-0669","doi":"https://doi.org/10.1158/0008-5472.can-07-0669","is_oa":false,"landing_page_url":"https://doi.org/10.1158/0008-5472.can-07-0669","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2005448885"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5046281810","display_name":"Joseph R. Garlich","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joseph R. Garlich","raw_affiliation_strings":["3Semafore Pharmaceuticals, Indianapolis, Indiana; and","Semafore Pharmaceuticals, Indianapolis, Indiana, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Semafore Pharmaceuticals, Indianapolis, Indiana; and","institution_ids":[]},{"raw_affiliation_string":"Semafore Pharmaceuticals, Indianapolis, Indiana, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111740527","display_name":"Pradip K.R De","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210113097","display_name":"Aflac (United States)","ror":"https://ror.org/01d3smq07","country_code":"US","type":"company","lineage":["https://openalex.org/I4210113097"]},{"id":"https://openalex.org/I4210146983","display_name":"Children's Healthcare of Atlanta","ror":"https://ror.org/050fhx250","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210146983"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pradip De","raw_affiliation_strings":["1Section of Hematology/Oncology, Department of Pediatrics, Aflac Cancer Center and Blood Disorders Service, Children's Healthcare of Atlanta and","AFLAC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Section of Hematology/Oncology, Department of Pediatrics, Aflac Cancer Center and Blood Disorders Service, Children's Healthcare of Atlanta and","institution_ids":["https://openalex.org/I4210146983"]},{"raw_affiliation_string":"AFLAC","institution_ids":["https://openalex.org/I4210113097"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012509754","display_name":"Nandini Dey","orcid":"https://orcid.org/0000-0002-5533-8784","observed_orcids":["https://orcid.org/0000-0002-5533-8784"]},"institutions":[{"id":"https://openalex.org/I4210113097","display_name":"Aflac (United States)","ror":"https://ror.org/01d3smq07","country_code":"US","type":"company","lineage":["https://openalex.org/I4210113097"]},{"id":"https://openalex.org/I4210146983","display_name":"Children's Healthcare of Atlanta","ror":"https://ror.org/050fhx250","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210146983"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nandini Dey","raw_affiliation_strings":["1Section of Hematology/Oncology, Department of Pediatrics, Aflac Cancer Center and Blood Disorders Service, Children's Healthcare of Atlanta and","AFLAC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Section of Hematology/Oncology, Department of Pediatrics, Aflac Cancer Center and Blood Disorders Service, Children's Healthcare of Atlanta and","institution_ids":["https://openalex.org/I4210146983"]},{"raw_affiliation_string":"AFLAC","institution_ids":["https://openalex.org/I4210113097"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086855070","display_name":"Jing Dong Su","orcid":"https://orcid.org/0000-0001-5389-734X","observed_orcids":["https://orcid.org/0000-0001-5389-734X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jing Dong Su","raw_affiliation_strings":["3Semafore Pharmaceuticals, Indianapolis, Indiana; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Semafore Pharmaceuticals, Indianapolis, Indiana; and","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058134724","display_name":"Xiaodong Peng","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xiaodong Peng","raw_affiliation_strings":["3Semafore Pharmaceuticals, Indianapolis, Indiana; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Semafore Pharmaceuticals, Indianapolis, Indiana; and","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033149936","display_name":"Antoinette Miller","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Antoinette Miller","raw_affiliation_strings":["3Semafore Pharmaceuticals, Indianapolis, Indiana; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Semafore Pharmaceuticals, Indianapolis, Indiana; and","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102095257","display_name":"Ravoori Murali","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ravoori Murali","raw_affiliation_strings":["4Department of Experimental Therapeutics, M. D. Anderson Cancer Center, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Department of Experimental Therapeutics, M. D. Anderson Cancer Center, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020581776","display_name":"Yiling Lu","orcid":"https://orcid.org/0000-0002-3662-2106","observed_orcids":["https://orcid.org/0000-0002-3662-2106"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yiling Lu","raw_affiliation_strings":["4Department of Experimental Therapeutics, M. D. Anderson Cancer Center, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Department of Experimental Therapeutics, M. D. Anderson Cancer Center, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005221518","display_name":"Gordon Brent Mills","orcid":"https://orcid.org/0000-0002-0144-9614","observed_orcids":["https://orcid.org/0000-0002-0144-9614"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gordon B. Mills","raw_affiliation_strings":["4Department of Experimental Therapeutics, M. D. Anderson Cancer Center, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Department of Experimental Therapeutics, M. D. Anderson Cancer Center, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067033760","display_name":"Vikas Kundra","orcid":"https://orcid.org/0000-0002-3262-4059","observed_orcids":["https://orcid.org/0000-0002-3262-4059"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vikas Kundra","raw_affiliation_strings":["4Department of Experimental Therapeutics, M. D. Anderson Cancer Center, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Department of Experimental Therapeutics, M. D. Anderson Cancer Center, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072559407","display_name":"H-K. Shu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"H-K. Shu","raw_affiliation_strings":["2Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia;","institution_ids":["https://openalex.org/I150468666"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025517379","display_name":"Qiong Peng","orcid":"https://orcid.org/0000-0002-8515-1136","observed_orcids":["https://orcid.org/0000-0002-8515-1136","https://orcid.org/0009-0001-3666-1359"]},"institutions":[{"id":"https://openalex.org/I4210113097","display_name":"Aflac (United States)","ror":"https://ror.org/01d3smq07","country_code":"US","type":"company","lineage":["https://openalex.org/I4210113097"]},{"id":"https://openalex.org/I4210146983","display_name":"Children's Healthcare of Atlanta","ror":"https://ror.org/050fhx250","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210146983"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Qiong Peng","raw_affiliation_strings":["1Section of Hematology/Oncology, Department of Pediatrics, Aflac Cancer Center and Blood Disorders Service, Children's Healthcare of Atlanta and","AFLAC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Section of Hematology/Oncology, Department of Pediatrics, Aflac Cancer Center and Blood Disorders Service, Children's Healthcare of Atlanta and","institution_ids":["https://openalex.org/I4210146983"]},{"raw_affiliation_string":"AFLAC","institution_ids":["https://openalex.org/I4210113097"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5025976004","display_name":"Donald L. Durden","orcid":"https://orcid.org/0000-0001-5386-1427","observed_orcids":["https://orcid.org/0000-0001-5386-1427"]},"institutions":[{"id":"https://openalex.org/I4210146983","display_name":"Children's Healthcare of Atlanta","ror":"https://ror.org/050fhx250","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210146983"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Donald L. Durden","raw_affiliation_strings":["1Section of Hematology/Oncology, Department of Pediatrics, Aflac Cancer Center and Blood Disorders Service, Children's Healthcare of Atlanta and","Computational Chemistry & Innovative Therapeutics"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Section of Hematology/Oncology, Department of Pediatrics, Aflac Cancer Center and Blood Disorders Service, Children's Healthcare of Atlanta and","institution_ids":["https://openalex.org/I4210146983"]},{"raw_affiliation_string":"Computational Chemistry & Innovative Therapeutics","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":11.2596,"has_fulltext":false,"cited_by_count":292,"citation_normalized_percentile":{"value":0.9930417,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":100},"biblio":{"volume":"68","issue":"1","first_page":"206","last_page":"215"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.0035000001080334187,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ly294002","display_name":"LY294002","score":0.847000002861023},{"id":"https://openalex.org/keywords/prodrugs","display_name":"prodrugs","score":0.6769999861717224},{"id":"https://openalex.org/keywords/pan-pi3k-inhibitor","display_name":"pan-PI3K inhibitor","score":0.8169999718666077},{"id":"https://openalex.org/keywords/integrin-targeting","display_name":"integrin targeting","score":0.7860000133514404},{"id":"https://openalex.org/keywords/tumor-angiogenesis","display_name":"tumor angiogenesis","score":0.7979999780654907},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.8510000109672546},{"id":"https://openalex.org/keywords/akt-phosphorylation","display_name":"Akt phosphorylation","score":0.8899999856948853},{"id":"https://openalex.org/keywords/pten","display_name":"PTEN","score":0.8059999942779541},{"id":"https://openalex.org/keywords/tumor-vasculature-targeting","display_name":"tumor vasculature targeting","score":0.8450000286102295},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7519999742507935},{"id":"https://openalex.org/keywords/u87mg-glioma","display_name":"U87 glioma","score":0.7289999723434448}],"concepts":[{"id":"https://openalex.org/C108215921","wikidata":"https://www.wikidata.org/wiki/Q603741","display_name":"Prodrug","level":2,"score":0.831890344619751},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.6587196588516235},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6237117648124695},{"id":"https://openalex.org/C2780394083","wikidata":"https://www.wikidata.org/wiki/Q539568","display_name":"Angiogenesis","level":2,"score":0.5893667340278625},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.550625741481781},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.53969407081604},{"id":"https://openalex.org/C2781322055","wikidata":"https://www.wikidata.org/wiki/Q423725","display_name":"Phosphoinositide 3-kinase","level":4,"score":0.5299991965293884},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5090886950492859},{"id":"https://openalex.org/C2776912716","wikidata":"https://www.wikidata.org/wiki/Q4042503","display_name":"LY294002","level":4,"score":0.4924215078353882},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.45144128799438477},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.33584609627723694},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.24509736895561218},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.17974281311035156},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.14966106414794922},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000081082","descriptor_name":"Phosphoinositide-3 Kinase Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D002867","descriptor_name":"Chromones","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D002867","descriptor_name":"Chromones","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D002867","descriptor_name":"Chromones","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008815","descriptor_name":"Mice, Inbred Strains","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000098","qualifier_name":"blood supply","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":true},{"descriptor_ui":"D009389","descriptor_name":"Neovascularization, Pathologic","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":true},{"descriptor_ui":"D009842","descriptor_name":"Oligopeptides","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D009842","descriptor_name":"Oligopeptides","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D009842","descriptor_name":"Oligopeptides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D009842","descriptor_name":"Oligopeptides","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D011355","descriptor_name":"Prodrugs","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011355","descriptor_name":"Prodrugs","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011355","descriptor_name":"Prodrugs","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D049109","descriptor_name":"Cell Proliferation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1158/0008-5472.can-07-0669","doi":"https://doi.org/10.1158/0008-5472.can-07-0669","is_oa":false,"landing_page_url":"https://doi.org/10.1158/0008-5472.can-07-0669","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},{"id":"pmid:18172313","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18172313","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer research","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1016969413","display_name":null,"funder_award_id":"CA 94233","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G7043661956","display_name":"Growth Factor Receptor in Breast Cancer Progression and Metabolic Regulation","funder_award_id":"P01CA099031","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G865444884","display_name":"The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer","funder_award_id":"P50CA083639","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":38,"referenced_works":["https://openalex.org/W1529396499","https://openalex.org/W1565533127","https://openalex.org/W1617532721","https://openalex.org/W1666849257","https://openalex.org/W1969744108","https://openalex.org/W1970174108","https://openalex.org/W1977070803","https://openalex.org/W1977340600","https://openalex.org/W1982085952","https://openalex.org/W1983704814","https://openalex.org/W1984418041","https://openalex.org/W2008167035","https://openalex.org/W2008872627","https://openalex.org/W2011282245","https://openalex.org/W2027044703","https://openalex.org/W2064504873","https://openalex.org/W2064695976","https://openalex.org/W2068912983","https://openalex.org/W2070805824","https://openalex.org/W2089190483","https://openalex.org/W2092452653","https://openalex.org/W2100470338","https://openalex.org/W2109854832","https://openalex.org/W2111613650","https://openalex.org/W2114787204","https://openalex.org/W2125861971","https://openalex.org/W2132279561","https://openalex.org/W2132482143","https://openalex.org/W2141149378","https://openalex.org/W2141820814","https://openalex.org/W2141942496","https://openalex.org/W2149881105","https://openalex.org/W2152624764","https://openalex.org/W2154608911","https://openalex.org/W2159530979","https://openalex.org/W2166525118","https://openalex.org/W2167761137","https://openalex.org/W4295234608"],"related_works":["https://openalex.org/W2506878738","https://openalex.org/W2241003473","https://openalex.org/W4241124341","https://openalex.org/W3019256966","https://openalex.org/W1999504067","https://openalex.org/W2589141964","https://openalex.org/W2023041438","https://openalex.org/W2061838553","https://openalex.org/W2123334268","https://openalex.org/W1189025943"],"abstract_inverted_index":{"PTEN":[0],"and":[1,17,38,46,64,85,94,108,152,168,188],"the":[2,44,70,78,82,115,144,153,195,203],"pan":[3,178,198],"phosphoinositide":[4],"3-kinase":[5],"(PI3K)":[6],"inhibitor":[7,180],"2-(4-morpholinyl)-8-phenyl-4H-1":[8],"benzopyran-4-one":[9],"(LY294002)":[10],"exert":[11],"significant":[12],"control":[13],"over":[14],"tumor-induced":[15],"angiogenesis":[16],"tumor":[18,71,83,110,150],"growth":[19,111],"in":[20,74,98,149,159,186],"vivo.":[21,160],"The":[22,101,171],"LY294002":[23,53],"compound":[24,80],"is":[25,58,88,95],"not":[26],"a":[27,50,132,176,192],"viable":[28,177],"drug":[29],"candidate":[30],"due":[31],"to":[32,60,66,81,105,164],"poor":[33],"pharmacologic":[34],"variables":[35],"of":[36,49,77,103,139,147,156,197,205],"insolubility":[37],"short":[39],"half-life.":[40],"Herein,":[41],"we":[42],"describe":[43],"development":[45],"antitumor":[47,167],"activity":[48,129,138],"novel":[51],"RGDS-conjugated":[52],"prodrug,":[54,135],"termed":[55],"SF1126,":[56],"which":[57],"designed":[59],"exhibit":[61,165],"increased":[62,128],"solubility":[63],"bind":[65],"specific":[67],"integrins":[68],"within":[69],"compartment,":[72],"resulting":[73],"enhanced":[75,113],"delivery":[76],"active":[79],"vasculature":[84],"tumor.":[86],"SF1126":[87,104,140,148,162,174],"water":[89],"soluble,":[90],"has":[91],"favorable":[92],"pharmacokinetics,":[93],"well":[96],"tolerated":[97],"murine":[99],"systems.":[100],"capacity":[102],"inhibit":[106],"U87MG":[107],"PC3":[109],"was":[112,141],"by":[114],"RGDS":[116],"integrin":[117],"(alpha":[118],"v":[119],"beta":[120,123],"3/alpha":[121],"5":[122],"1)":[124],"binding":[125],"component,":[126],"exhibiting":[127],"compared":[130],"with":[131,143],"false":[133],"RADS-targeted":[134],"SF1326.":[136],"Antitumor":[137],"associated":[142],"pharmacokinetic":[145],"accumulation":[146],"tissue":[151],"pharmacodynamic":[154],"knockdown":[155],"phosphorylated":[157],"AKT":[158],"Furthermore,":[161],"seems":[163],"both":[166],"antiangiogenic":[169],"activity.":[170],"results":[172],"support":[173,190],"as":[175],"PI3K":[179,199],"for":[181,191,202],"phase":[182],"I":[183],"clinical":[184],"trials":[185],"cancer":[187],"provide":[189],"new":[193],"paradigm,":[194],"application":[196],"inhibitory":[200],"prodrugs":[201],"treatment":[204],"cancer.":[206]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2005448885","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":12},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":11},{"year":2020,"cited_by_count":11},{"year":2019,"cited_by_count":9},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":10},{"year":2016,"cited_by_count":15},{"year":2015,"cited_by_count":17},{"year":2014,"cited_by_count":27},{"year":2013,"cited_by_count":27},{"year":2012,"cited_by_count":22}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
